Telix Assets

About: Girentuximab antibody was in-licensed from Wilex AG, a small German biotech company, who completed the initial Phase 3 study of the imaging agent as a patient selection tool. Telix has now in-licensed this product and is developing 124I-TX250 for the diagnosis of clear cell renal cell carcinoma (ccRCC) and 177Lu-TX250 for the treatment of metastatic ccRCC.

Mechanism of Action: The chimeric antibody cG250 (girentuximab) binds carbonic anhydrase IX; a cell-surface antigen which is highly and homogenously expressed in over 90% of ccRCC patients.  It is also expressed in a significant proportion of other cancer types including non-small cell lung carcinoma (NSCLC) and ovarian cancer.

Importance in ccRCC diagnosis: There is a significant unmet need for better diagnostic methods for preoperative characterisation of ccRCC. With current standard of care, renal masses enhanced on CT are malignant until otherwise proven benign by biopsy. Biopsies are invasive and costly and have mixed accuracy data, depending on the centre, size and location of the tumour.

Telix Images-10

About:Telix is developing 177Lu-TX591 as a late-stage imaging and treatment compound. It is based on the huJ591 humanised mAb developed by Neil Bander at Weill Cornell Medical College (Urology).

Mechanism of Action: The humanised monoclonal antibody huJ591 targets PSMA (Prostate Specific Membrane Antigen), which is over-expressed in prostate cancer. TX591 labelled with 177Lu has been under formal development for the treatment of castrate-resistant prostate cancer, and is to date the most extensively characterised PSMA-targeted therapy agent.

Need for novel treatments in prostate cancer: Late-stage/end-stage metastatic prostate cancer patients have very few treatment options beyond chemotherapy. Despite initial therapy, about 30% of men suffer from relapse suggesting that there is a need for further treatment options in patients with late-stage disease.

Telix Images-14

About: The technology behind TX101 was developed in collaboration with several leading German nuclear medicine centres and in-licensed to Therapeia GmBH & Co Kg, a German company privately owned by Dr. Andreas Kluge (Telix co-founder). Telix has in-licensed this technology and is developing 124I-TX101 for diagnosis and 131I-TX101 for therapy of glioblastoma multiforme (GBM).

Mechanism of Action: TX101 targets LAT-1 (L-type amino acid transporter), which is highly expressed in human cancer tissues, and is over-expressed in most gliomas. The mechanism of action of TX101 not only delivers potent targeted radiation but it also increases the efficacy of external beam radiation, used as standard of care in GBM treatment.

Need for treatment options: GBM is one of the most challenging brain tumours to treat. It is an aggressive disease and median survival is usually less than 1 year after diagnosis. Standard of care is surgical resection of the tumour, followed by radiotherapy and temozolomide (TMZ) treatment. While TMZ can be effective, it must be administered at high doses because of its short half-life, resulting in significant adverse events.

Telix Images-15